資料來源：https://www.thestreet.com/story/13957207/1/eli-lilly-acquires-colucid-pharma-adds-migraine-drug-to-pipeline.html

Eli Lilly (LLY) is buying CoLucid Pharmaceuticals (CLCD) for $960 million in cash, adding a late-stage migraine pill candidate to the pharma giant's pain management portfolio.

Under deal terms announced Wednesday, CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.

CoLucid, based in Cambridge, Mass, is developing a pill known as lasmiditan for the acute treatment of migraine headaches. Lasmiditan works differently from the conventional class of drugs known as triptans, which are now the standard of care for migraines.

A successful phase III study of lasmiditan was completed in September. A second phase III study is expected in the second half of 2017. If that study is also positive, a U.S. regulatory filing for approval could occur in 2018.

Lasmiditan was actually discovered by Lilly and licensed out to CoLucid in 2005. CoLucid developed the drug and went public in May 2015 at $10 per share. Now, the company and the migraine drug are being folded back into Lilly.

"We are excited that lasmiditan will be back at Lilly, where it was originally discovered, for the conclusion of phase III development and potential commercialization," said Thomas Mathers, CoLucid's CEO, in a statement. "We are proud of the work that CoLucid has done to develop lasmiditan, and we believe Lilly's expertise in pain and commitment to innovation are a natural fit to potentially bring this medicine to patients."

Lilly's existing pain management pipeline includes galcanezumab, a potential medicine in late-stage clinical development for the prevention of migraine and cluster headache. In addition, tanezumab is being studied, in collaboration with Pfizer ( PFE) , for the treatment of multiple pain indications, including osteoarthritis, lower back and cancer pain.